Xadago

Xadago (safinamide) is an oral medication used alongside levodopa/carbidopa to manage Parkinson’s disease symptoms like motor fluctuations. This MAO-B inhibitor helps extend 'on' time by supporting dopamine activity in the brain. Suitable for adults with mid-to-late stage Parkinson’s experiencing 'off' episodes.

Xadago is prescribed to improve motor symptoms in people with Parkinson’s disease who experience 'off' periods despite taking levodopa/carbidopa. It works by slowing the breakdown of dopamine in the brain, which can help maintain smoother movement control throughout the day. Patients often notice reduced rigidity, tremors, and bradykinesia during 'on' phases. It is not a standalone treatment but used as an add-on therapy.

Users may experience improved mobility and reduced 'off' time when taking Xadago as directed. Some report feeling more alert or steady during daily activities, particularly in the hours after a dose. Effects vary by individual, and noticeable changes may take several weeks to appear. It does not cure Parkinson’s but aims to manage symptoms over time.

Xadago should be taken exactly as prescribed, typically once daily with food. Avoid sudden dose changes without medical guidance to reduce the risk of side effects. Keep follow-up appointments to monitor progress and adjust therapy as needed. Store at room temperature away from moisture and heat.

Avoid combining Xadago with other MAO inhibitors, opioids, or serotonin-boosting medications due to the risk of serious reactions. Limit alcohol and check with a healthcare provider before using over-the-counter supplements. Certain antidepressants and cold remedies may also interact, so disclose all current medications. CYP inhibitors can affect how Xadago is processed in the body.